There is considerable evidence that malignant transformation need not eliminate the potential for a cell to express its developmental capabilities. This review explores the process whereby polar compounds, hexamethylene bisacetamide (HMBA) in particular, induce murine erythroid leukemoid cells (MELC) to express the differentiated erythroid phenotype, including hemoglobin production and cessation of cell division. This is a multi-step process which, although the mechanisms of action of HMBA are not yet fully understood, is amenable to experimental definition and analysis. Early effects, including changes in protein kinase C activity, in ion transport, and in expression of certain nuclear proto-oncogenes, have been examined in relation to the onset of terminal cell differentiation. This experimental experience has formed the context for initiating preliminary clinical studies designed to examine the phannacology of HMBA and to explore its potential for modifying the natural history of cancer.
Introduction
Characterization of inducer-mediated alterations in the phenotype of transformed cells, employing hexamethylene bisacetamide (HMBA-induced murine erythroleukemia (MEL) cell differentiation as a model, has provided considerable understanding of the changes involved in this complex, multistep process (1) (2) (3) . These investigations have provided, in part, a basis for considering the use of cytodifferentiation agents to overcome the maturation defect commonly associated with cell transformation, and to induce loss of proliferative capacity, as an approach to therapy of various tumors (4) (5) (6) (7) (8) .
Studies of HMBA-induced MEL cells have generated a considerable body of knowledge about the process by which a proliferating population of precursor cells, with the potential for expressing a differentiated phenotype (in this case an erythroid cell phenotype) withdraws from the cell division cycle and expresses those genes characteristic of the differentiated phenotype. However, our understanding of the process is far from complete. We are only beginning to define the mechanisms by which these cells receive proliferative or differentiation signals from their environment and the ways in which these signals are transduced to alter nuclear events, such as DNA replication and specific gene expression.
This review focuses on HMBA-induced MEL cell differentiation to the terminal erythroid phenotype. It will summarize studies of inducer action during the early, latent period and the later, irreversible alterations involving expression of genes for products characteristics of the differentiated erythroid phenotype. We will also review studies with cell lines in culture that have provided a basis for phase I clinical trials with HMBA as a potential cancer therapy.
Potential of Transformed Cells to Differentiate
The polar compound, HMBA, can circumvent the virusinduced block of MEL cell development and cause these cells to differentiate with loss of proliferative capacity (8, 9) . Thus, transformation does not eliminate the poten-tial of MEL cells to express their genetic program of erythroid differentiation (1) (2) (3) . Additional evidence that tumor cells are not necessarily irreversibly blocked with respect to differentiation derives from studies of a number of systems. For example, compounds structurally related to HMBA, as well as a number of other agents, can induce the expression of differentiated characteristics in MEL cells, as well as a variety of different transformed cells in vitro (Table 1) (1-3,8-32 ). This concept is also supported by the behavior of temperature-sensitive transforming viruses that block nornal development at permissive temperatures but permit expression of the differentiated phenotype at nonpermissive temperatures (33, 34) . Other studies that support this hypothesis concern malignant teratocarcinoma cells that, implanted into the inductive environment of the early mouse embryo, differentiate and contribute to the normal organs of the chimeric mouse (35 (39, 40) . This early or latent period is followed by a period during which an increasing proportion of the population express characteristics of terminal differentiation (Fig. 2) .
HMBA-mediated MEL cell terminal differentiation is a multistep process (41, 42) . During the early period, the inducer initiates a number of metabolic changes that precede irreversible commitment. Among these changes are alterations in membrane permeability that involve sodium, potassium, and calcium flux (43) (44) (45) , alterations in membrane fluidity (46, 47) , changes in cell volume, a transient increase in cyclic AMP concentration (48-49), a prompt increase in membrane associated protein kinase C (PKC) activity, the appearance in the cytosol of a Ca2 + and phospholipid-independent form of PKC, presumably generated by proteolytic cleavage of membrane-bound PKC (50) , and a change in expression of a number of genes, including c-myb, c-myc, c-fos, and p53 gene (51) (52) (53) (54) 
Modulation of Gene Expression
During the early period, HMBA induces a modulation in expression of a number of genes, among which are c-myb, c-myc, c-fos, and p53 (51) (52) (53) (54) . These genes control products that are localized in the nucleus and may be involved in the regulation of gene expression and cell replication (59) (60) (61) (62) (63) . However, the specific action of the protein products of these genes is not known. In MEL cells in culture with HMBA, the level of c-myc mRNA decreases markedly within the first hour of culture. A decrease in c-myb mRNA level occurs within 1 to 4 hr, whereas c-fos mRNA, which is almost undetectable in (71) , the inducer does cause certain changes in chromatin structure, including appearance of DNAse I hypersensitive sites within 100 base pairs 5' of both the al-and Pmaj-genes (66, 67, 71) and the appearance of another DNAse I hypersensitive site about 3000 base pairs upstream of the cap site of the Pmaj-globin (72 
Mechanism of Action of HMBA
A working model for the effects of HMBA on MEL cells is presented in Figure 2 . The mechanism of action of HMBA is not known. There is evidence that HMBA and related polar compounds cause a significant decrease in the levels of phosphatidylinositol metabolites, including inositol triphosphate and diacylglycerol, within 2 hr of onset of culture (74) . Diacylglycerol activates the Ca2 + and phospholipid dependent PKC activity (75) . The tumor promoter TPA, which activates PKC and for which PKC is a specific receptor, can suppress HMBA-induced differentiation in MEL cells (76, 77) . We have recently reported evidence that PKC activity has a role in inducer-mediated modulation of late gene expression in MEL cell differentiation, based on the following findings (50): a) HMBA induces the formation of a soluble, proteolytically activated form of PKC that is catalytically active in the absence of Ca2 + and phospholipid; b) the protease inhibitor, leupeptin, blocks formation of this activated form of the kinase and inhibits HMBA-induced MEL cell hemoglobin accumulation; c) TPA, which causes depletion of total PKC activity, inhibits HMBA-induced MEL cell terminal dif-ferentiation but does not prevent the inducer-mediated early modulation in expression of c-myc, c-myb, and p53 genes; d) MEL cells depleted of PKC activity by TPA are resistant to induction by HMBA; e) removal of TPA leads to restoration of MEL cell sensitivity to HMBA, correlated with progressive reaccumulation of PKC activity. If, as suggested, PKC activation has a role in the pathway of HMBA-induced modulation of gene expression and consequent differentiation and loss of capacity for cell division, it may involve the phosphorylation of proteins critical to the regulation of gene expression and DNA replication.
There is evidence for other inducer-mediated events that may also be involved in the pathway leading to expression of the differentiated phenotype in MEL cells. These include single strand breaks in DNA (78) (79) (80) , changes in configuration of chromatin structure (81, 82) , and expression or suppression of specific oncogenes (as described above) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) . Recently, it has been shown, using the technique of cell fusion, that MEL cell differentiation may involve a synergistic effect of two distinct intracellular reactions (83) , one originating from the inhibition or cessation of DNA replication by diverse agents, and the other involving a reaction triggered specifically by inducing agents such as HMBA. The former reaction appears not to be specific to MEL cells, whereas the latter is specific to MEL cells and inducible by HMBA. The induced activity is transient and inhibited by TPA (84, 85) . Partial purification of the protein factors responsible for these reactions has been reported (86, 87 tic fashion until over 95% of the population are recruited to a state of irreversible commitment to terminal differentiation and terminal cell division by 48 to 60 hr. Commitment is associated with persistent suppression of c-myb gene expression and elevated levels of c-fos mRNA, while c-myc mRNA returns to the level in uninduced cells. By 36 to 48 hr, transcription of the globin genes has increased by 10-to 30-fold, whereas transcription from the rRNA genes is suppressed.
The in vitro studies with HMBA induction of MEL cells provide a basis for considering polar agents, such as HMBA, for clinical therapy of human cancers. Based on these in vitro studies it is likely that, to be effective, HMBA must be administered in doses that achieve adequate concentrations in the serum (probably in the neighborhood of 3 to 5 mM), that these concentrations be maintained over a prolonged period of time, and that the biological effect of the agent be monitored by indices of the particular differentiated phenotype of the cancer being studied.
